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Cocaine-Induced Loss of White Matter Proteins in
the Adult Mouse Nucleus Accumbens Is Attenuated
by Administration of a -Lactam Antibiotic during
Cocaine WithdrawalJane Kovalevich,* Gladys Corley,†‡ William Yen,*
Scott M. Rawls,†‡ and Dianne Langford*
From the Departments of Neuroscience * and Pharmacology,†
and the Center for Substance Abuse Research,‡ Temple University
School of Medicine, Philadelphia, Pennsylvania
We report significantly decreased white matter pro-
tein levels in the nucleus accumbens in an adult
mouse model of chronic cocaine abuse. Previous
studies from human cocaine abuse patients show
disruption of white matter and myelin loss, thus
supporting our observations. Understanding the
neuropathological mechanisms for white matter
disruption in cocaine abuse patients is complicated
by polydrug use and other comorbid factors, hin-
dering the development of effective therapeutic
strategies to ameliorate damage or compliment re-
habilitation programs. In this context, our data
further demonstrate that cocaine-induced loss of
white matter proteins is absent in mice treated with
the -lactam antibiotic, ceftriaxone, during cocaine
withdrawal. Other studies report that ceftriaxone, a
glutamate transporter subtype-1 activator, is neuro-
protective in murine models of multiple sclerosis,
thereby demonstrating potential therapeutic prop-
erties for diseases with white matter loss. Cocaine-
induced white matter abnormalities likely contrib-
ute to the cognitive, motor, and psychological
deficits commonly afflicting cocaine abusers, yet
the underlying mechanisms responsible for these
changes remain unknown. Our observations de-
scribe an adult animal model for the study of co-
caine-induced myelin loss for the first time, and
highlight a potential pharmacological intervent-
ion to ameliorate cocaine-induced white matter
loss. (Am J Pathol 2012, 181:1921–1927; http://dx.doi.org/
10.1016/j.ajpath.2012.08.013)In 2009, it was estimated that nearly 5 million Americans
12 years of age had used cocaine during the past
year.1 Imaging studies and postmortem microarray data
from human cocaine abuser populations suggest that
chronic abuse disrupts white matter (WM) integrity and
myelin gene expression in discrete brain regions, includ-
ing the nucleus accumbens (NA)2,3,4 As human studies
of abuse are often confounded by polydrug use and
co-morbid conditions, in vivo animal studies are needed
to delineate pathways affected by cocaine that may con-
tribute to myelin loss to highlight potential treatment tar-
gets. In a recent magnetic resonance imaging study, WM
abnormalities were reported in active cocaine users.5
However, the WM abnormalities resolved to some degree
in patients with prolonged abstinence, suggesting recov-
ery potential, making results from our study relevant for
adjuvant therapies during rehabilitation programs. The
mechanisms involved in cocaine-induced myelin loss are
unknown, but may involve glial excitotoxicity.6–13 Even
less clear are mechanisms that may contribute to white
matter recovery or protection.
Some studies have evaluated the effects of maternal
cocaine abuse on myelination defects in offspring,14
however, investigations of cocaine-mediated myelin dis-
ruption in adult animal models have not been previously
described. Recent studies in our laboratory uncovered a
new model by which cocaine significantly decreases WM
proteins in adult mice. Chronic cocaine administration
followed by withdrawal and challenge resulted in a sig-
nificant decrease in a number of myelin-associated pro-
teins, including myelin basic protein (MBP), proteolipid
protein (PLP), myelin oligodendrocyte glycoprotein
(MOG), and myelin-associated glycoprotein (MAG) in the
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transporter-1 (GLT1) activator2,15,16 was administered
during the withdrawal period, no evidence of WM loss
was observed. Ceftriaxone has displayed anti-addictive
and neuroprotective properties in murine models of co-
caine abuse and multiple sclerosis, respectively,2,17,18
although the exact mechanisms through which it is acting
are unknown. Additionally, recent studies by Sondheimer
and Knackstedt19 reported that ceftriaxone prevented
the induction of cocaine sensitization in a rat model of
cocaine abuse.
Our results report two important observations in an
adult mouse model: cocaine-induced myelin loss and
attenuation of cocaine-induced WM protein loss in ceftri-
axone-treated mice. The observation that ceftriaxone ne-
gates cocaine-induced WM loss provides clues as to the
mechanism through which cocaine may exert its effects
on WM protein levels and points to alterations in gluta-
matergic homeostasis. Expanded studies are underway
to address this hypothesis.
Materials and Methods
Animals
This study used 10-week-old male C57BL/6 mice
(Charles River Laboratories, Wilmington, MA). All proce-
dures were approved by and conducted in accordance
with Temple University Institutional Animal Care and Use
Committee guidelines. Mice were singly housed in an
animal facility with constant airflow, controlled tempera-
ture (21–23°C), and a 12-hour light/dark cycle, and the
mice were supplied with food and water ad libitum. The
mice were divided into five groups with 8 to 10 mice per
group. Cocaine hydrochloride (Sigma-Aldrich, St. Louis,
MO) was dissolved in sterile water and administered at
15 mg/kg i.p. Ceftriaxone sodium (American Regent Inc.,
Shirley, NY) was dissolved in sterile water and adminis-
tered (200 mg/kg i.p.). Injection volumes were 1 mL/100
g per body weight.
The paradigm for each group consisted of a total of 47
days of injections: 3 days pretreatment with the vehicle
(sterile water) or ceftriaxone, 14 days of cocaine or vehi-
cle with or without ceftriaxone, followed by 30 days of
withdrawal with either vehicle or ceftriaxone on each day.
The control group received a total of 47 days of vehicle.
The ceftriaxone only (Ceft) group received ceftriaxone for
17 days, followed by 30 days of vehicle. The cocaine only
(Coc) group received 3 days vehicle, followed by 14 days
of cocaine, and 30 days of vehicle. The cocaine plus
ceftriaxone (Coc with Ceft) group received 3 days of
ceftriaxone, followed by 14 days of cocaine plus ceftri-
axone, and then 30 days of vehicle. The cocaine then
ceftriaxone (Coc then Ceft) group received 3 days of
vehicle, 14 days of cocaine, and 30 days of ceftriaxone.
All mice received a single challenge dose of cocaine (15
mg/kg i.p.) 24 hours before euthanasia.Tissue Harvest
Animals were heavily anesthetized with 5% isoflurane
and decapitated. Brains were removed and placed in
ice-cold PBS. The NA was dissected from each brain,
and the tissue was homogenized by mechanical dounce
disruption on ice in lysis buffer (50 mmol/L Tris-HCl, pH
7.5, 150 mmol/L NaCl, 0.5% NP-40, 1:200 protease in-
hibitor cocktail; Calbiochem, San Diego, CA). Once com-
pletely homogenized, samples were centrifuged at
13,000  g at 4°C for 5 minutes. The protein (contained
in Supernatant) was collected, and protein concentra-
tions were determined via the Bradford assay. Protein
samples were stored at 80°C. For immunohistochemi-
cal analyses, whole brains were removed, fixed in forma-
lin, embedded in paraffin, sectioned, and processed for
immunolabeling, described as follows.
Western Analyses
Equal amounts of protein were loaded onto pre-cast midi-
gels (4 to 12% Bis-Tris; Invitrogen, Carlsbad, CA), sepa-
rated by electrophoresis and transferred onto nitrocellu-
lose membranes (Bio-Rad, Hercules, CA). Membranes
were blocked in 5% nonfat milk in 1 Tris-buffered saline,
0.1% Tween-20 for 30 minutes before incubation with
primary antibodies. Primary antibodies included: myelin
basic protein (1:10,000; Millipore, Danvers, MA), MOG
(1:1000; Abcam, Cambridge, MA), MAG (1:2000; Santa
Cruz Biotechnology, Santa Cruz, CA), PLP, and PLP al-
ternate isoform protein (DM20) (1:2000; Abcam), cleaved
caspase-3, (1:500; Millipore), GLT1 (1:20,000; Millipore),
or loading control glyceraldehydes-3-phosphate dehy-
drogenase (1:4000; Santa Cruz, CA). Membranes were
incubated for either 2 hours at 23°C or overnight at 4°C,
washed in 1 Tris-buffered saline, 0.1% Tween-20, incu-
bated with appropriate secondary anti-mouse or anti-
rabbit antibodies (1:10,000; Thermo Scientific, Lafayette,
CO) for 1 hour at 23°C, and developed with enhanced
chemiluminescence (ECL) or ECL PRIME (Amersham
Pharmacia Biotech, Piscataway, NJ). Band intensities
were calculated using ImageJ software (NIH, Bethesda,
MD) and were normalized to loading control glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH).20
Immunofluorescence Labeling
Coronal sections (4 m) of formalin-fixed, paraffin-em-
bedded tissues were placed on electromagnetically
charged glass slides. The slides were deparaffinized in
xylene and rehydrated through descending grades of
ethanol up to water. After nonenzymatic antigen retrieval
in 0.01 M sodium citrate buffer (pH 6.0) for 30 minutes at
97°C in a vacuum oven, tissue was permeabilized in
0.2% Triton X-100 in 1 PBS for 10 minutes, and slides
were washed with 1 PBS and placed in blocking solu-
tion (5% normal goat or horse serum; Vector Laborato-
ries, Burlingame, CA) for 2 hours. Primary antibodies
consisted of MBP (1: 200; Millipore), neurofilament, (1:
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cleaved caspase-3 (1:50; Millipore). Sections were incu-
bated with primary antibody overnight in a dark, humid-
ified chamber at 23°C, rinsed three times with PBS, and
incubated with fluorescein isothiocyanate (1:500; Vector
Laboratories) or Texas Red (1:500; Vector Laboratories)
conjugated secondary antibodies for 1 hour at 23°C in
the dark. Sections were again washed three times with
PBS, re-blocked (5% normal goat or horse serum), incu-
bated overnight with the second primary antibody,
washed, and again incubated with the appropriate sec-
ondary antibody. Slides were cover slipped with an aque-
ous-based mounting medium containing DAPI for nuclear
labeling (Vectashield; Vector Laboratories), visualized
with a Nikon UV inverted microscope, and processed
with deconvolution software (Slidebook 4.0; Intelligent
Imaging, Denver, CO), allowing acquisition of multiple
0.25 m thick digital sections and 3-dimensional recon-
struction of the image.
Statistical Analysis
All data were analyzed using one-way analysis of vari-
ance with post hoc testing where appropriate using Graph-
Pad Prizm (GraphPad Software Inc., San Diego, CA) and
results are expressed as mean  SEM, n  8. Values of
P  0.05 were considered statistically significant. The few-
est mice required to detect differences with an -level of
0.05 and 80% power were used.
Results
Chronic cocaine administration (15 mg/kg daily for 14
days) followed by 30-day withdrawal and cocaine chal-
lenge (15 mg/kg, once) resulted in significant decreases
in myelin-associated proteins in the NA (Figure 1A). White
matter deficits were not observed in the prefrontal cortex
or other brain regions assessed (data not shown). During
withdrawal, mice were given vehicle injections every day
for 30 days, followed by a single dose cocaine challenge
on the last day. After withdrawal, MBP levels in cocaine-
treated animals were 38% lower than controls (P  0.05),
and PLP levels were 55% lower than controls (P  0.001)
(Figure 1A). Likewise, in cocaine-treated animals, DM20
was decreased by 33% compared to controls, but levels
did not reach statistical significance (or were NS) (Figure
1A). Myelin basic protein and PLP/DM20 constitute be-
tween 60 and 80% of the total myelin sheath in human
and rodent brains. Much of the remaining 20 to 40% of
the myelin sheath consists of MOG and MAG. MOG and
MAG were decreased significantly (P 0.001) by 42 and
58%, respectively, compared to control levels (Figure
1A). Double-immunofluorescence labeling of NA tissue
from a representative control mouse showed robust MBP
immunoreactivity (green) and associated neurofilament
(red) for axons (Figure 1B). On the other hand, in a cocaine-
treated mouse, sparse MBP immunoreactivity (green) was
observed in the NA (Figure 1C). Interestingly, neurofilament
immunolabeling of the cocaine-treated mouse remained ro-
bust, suggesting the presence of unmyelinated axons (Fig-ure 1C). These data indicate that 14 days of cocaine ad-
ministration leads to significant loss of MBP, PLP, MOG, and
MAG WM proteins after 30 days of cocaine withdrawal and
a single challenge dose.
Mice administered cocaine for 14 days followed by
daily injections of ceftriaxone (200 mg/kg) during the
30-day withdrawal showed no significant loss of myelin
proteins (Figure 2) (compare the control group to the Coc
then Ceft group). In mice in which ceftriaxone was given
with cocaine for 14 days followed by a vehicle during
withdrawal the loss of WM was similar to levels in the Coc
group (Figure 2, A–F) (compare the Coc group to the Coc
with Ceft group). Likewise, mice given ceftriaxone only for

















































Figure 1. Effects of cocaine on white matter protein levels in the nucleus
accumbens. A: Levels of MBP (*P 0.05) PLP, MOG, MAG (**P 0.001), PLP
alternate isoform (DM20) (NS), in mice administered cocaine (15 mg/kg) for
14 days, followed by 30 days vehicle during withdrawal and a single chal-
lenge dose of cocaine. n  8 to 10 mice per group with one-way analysis of
variance with Bonferroni’s multiple comparison post hoc testing. B and C:
Double immunofluorescence labeling of nucleus accumbens from control
(B), and mice treated with cocaine for 14 days, 30 days withdrawal (C),
followed by cocaine challenge. Tissues are labeled with MBP in green,
neurofilament in red, and nuclei are labeled in blue with DAPI. Original
magnification, 40. Scale bar  10 m.levels similar to the control group (Figure 2, A–F) (com-
MBP in
, myelin
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AJP December 2012, Vol. 181, No. 6pare the control group to the Ceft group). These data
show that administration of ceftriaxone during the with-
drawal period after 14 days of cocaine administration
prevents MBP, PLP, MOG, and MAG WM protein loss
upon withdrawal and challenge.
Double immunofluorescence labeling of NAc tissue
from a representative control mouse showed robust MBP
(green) and neurofilament (red) immunoreactivity (Fig-
ures 1B and 2G). On the other hand, in a cocaine-
treated mouse, sparse MBP immunoreactivity (green)
was observed in the NA (Figures 1C and 2H). In a
mouse treated with cocaine for 14 days followed by
ceftriaxone during withdrawal MBP labeling appeared
similar to levels in the control (compare green) (Figure
2, G and I). However, co-localization (yellow) of neu-
rofilament (red) with MBP (green) in mice given co-
caine then ceftriaxone during withdrawal appears to be
decreased (Figure 2I). This pattern may suggest that
even though MBP levels are normal, association with
axons may be altered.
Cocaine-mediated changes in glutamate signaling







































































Figure 2. Effects of ceftriaxone administration on WM during withdrawal f
mouse from each group. GAPDH was used as a loading control. B–F: WM
withdrawal (Ceft); 14 days cocaine followed by 30 days vehicle during withd
cocaine, and 30 days of vehicle during withdrawal (Coc with Ceft); 14 days o
Ceft). B: Quantification of MBP. *P  0.05, **P  0.01. C: PLP. *P  0.001,
glycoprotein (MOG). *P 0.001, **P 0.01. F:MAG. *P 0.001, **P 0.01 le
multiple comparison post hoc testing. G–I: Double immunofluorescence lab
followed by 30 days vehicle during withdrawal and a single dose challenge o
withdrawal and a single dose challenge of cocaine. Tissues are labeled with
magnification, 40. Scale bar  10 m. DM20, PLP alternate isoform; MAGmay be responsible in part for the loss of WM proteinsobserved in cocaine-treated mice. Likewise, ceftriaxone
(a GLT1 activator) abolished cocaine-induced white mat-
ter protein loss, suggesting a contribution of glutamate
excitotoxicity cell death. In this context, expression
levels of GLT1 and cleaved caspase-3, which is indic-
ative of apoptosis, were assessed. GLT1 levels in the
cocaine-treated group were lower than levels in the
control group, although changes did not reach statis-
tical significance (Figure 3, A and B). Because GLT1 is
responsible for the clearance of more than 90% of
glutamate in the synaptic cleft, even slight changes in
GLT1 expression could have a significant impact on
synaptic glutamate levels.21 In the cocaine-treated
group, GLT1 levels were significantly lower than Ceft
only and the Coc then Ceft groups (P  0.01) (Figure 3,
A and B). In the cocaine-treated group, caspase-3
levels were significantly greater than the control (P 
0.05) and Coc then Ceft groups (P  0.01) (Figure 3, C
and D) in which caspase-3 was nearly undetectable. In
this context, other studies have shown that glutamate
excitotoxicity induces apoptosis in oligodendrocytes in
a caspase-dependent manner.22,23 To assess if oligo-
H Cocaine I Coc then Ceft






























































































aine. A: Representative Western blot of 10 g protein from NAc from one
levels in control; 17 days ceftriaxone followed by 30 days vehicle during
oc); 3 days ceftriaxone pretreatment followed by 14 days of ceftriaxone and
e followed by 30 days ceftriaxone (200 mg/kg) during withdrawal (Coc then
05. D: PLP alternate isoform (DM20). *P  0.05. E: Myelin oligodendrocyte
8 to 10 mice per group with one-way analysis of variance with Bonferroni’s
nucleus accumbens from (G) control; (H) cocaine (15 mg/kg) for 14 days,
e; (I) cocaine (15 mg/kg) for 14 days, followed by 30 days ceftriaxone during

















f cocaindendrocytes in cocaine-treated mice without Ceft showed
C1-imm
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AJP December 2012, Vol. 181, No. 6increased caspase-3 cleavage, double immunofluores-
cence labeling for activated caspase-3 and an oligoden-
drocyte-specific marker, CC1, was conducted. CC1 immu-
noreactive oligodendrocytes (red) in cocaine-treated mice
showed immunolabeling for caspase-3 (green) (Figure 3F,
arrowheads), whereas, control mice (Figure 3E) and Coc
then Ceft mice (Figure 3G) showed nearly undetectable
caspase-3 immunolabeling.
Although detailed behavior assessments are beyond
the scope of this report, we observed that ceftriaxone-
treated mice and mice that received cocaine followed by
ceftriaxone during withdrawal (Coc then Ceft) did not
exhibit increased activity as observed in cocaine-treated
mice (Coc) and in mice treated with cocaine and ceftri-
axone simultaneously (Coc with Ceft) (data not shown).
Thus, the prominent clinical signs observed in some of
these groups included increased activity. Control, Ceft,






















































Figure 3. Evidence of decreased glutamate subtype transporter-1 (GLT1) an
levels in NAc of control; 17 days ceftriaxone only (Ceft) followed by 30 days
during withdrawal; 3 days Ceft pretreatment followed by 14 days of ceftriax
of cocaine followed by 30 days ceftriaxone (Coc then Ceft) during withdraw
NAc from one mouse from each group. GADPH was used as a loading contr
from NAc from one mouse from each group. GAPDH was used as a loading c
cocaine followed by 30 days vehicle during withdrawal (Coc); 14 days of co
10 mice per group with one-way analysis of variance with Bonferroni’s mu
labeled with an antibody against cleaved caspase-3 in green, CC1, an oligod
control show robust CC1-immunoreactivity (red) with no evidence of cas
immunoreactivity (red) with evidence of caspase-3 activity (green, arro
cocaine treated mice that received ceftriaxone during withdrawal show C
magnification, 100. Scale bar  10 m.another.Discussion
Several pathways likely contribute to cocaine-mediated
WM loss. Among potential contributors are changes in
levels of dopamine, cellular retinoic acid, or glutamate. In
this regard, acute central nervous system effects of co-
caine administration include increased extracellular do-
pamine in the synaptic cleft due to the blockade of the
dopamine transporter.24 Activation of dopaminergic D3
receptors decreases differentiation of oligodendrocyte
precursor cells into mature oligodendrocytes and inhibits
myelin formation.25 In addition, our laboratory has dem-
onstrated that chronic cocaine abuse alters retinoic acid
signaling and decreases expression of retinoid X recep-
tor isoform-.26 These findings are significant in the con-
text of the current study, because cellular levels of reti-
noic acid regulate both MBP and PLP.27,28 Furthermore,







































sed caspase-3 activity in oligodendrocytes of cocaine-treated mice. A: GLT1
during withdrawal; 14 days cocaine only (Coc) followed by 30 days vehicle
cocaine (Coc with Ceft) and 30 days of vehicle during withdrawal; 14 days
0.01. B: Representative Western blot of GLT1 levels in 10 g protein from
presentative using Western blot of cleaved caspase-3 levels in 40 g protein
*P  0.05, **P  0.01. D: Cleaved caspase-3 protein levels in control; 14 days
llowed by 30 days ceftriaxone during withdrawal (Coc then Ceft). n  8 to
mparison post-hoc testing. E–G: NAc tissues from representative mice are
te-specific maker in red, and nuclei in blue with DAPI. E: NAc tissues from
ctivity. F: NAc tissues from cocaine-treated mice show decreased CC1-
s) associated with CC1-1 oligodendrocytes (red). G: NAc tissues from













wheadretinoid X receptor isoform- in oligodendrocyte matura-
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AJP December 2012, Vol. 181, No. 6tion and remyelination after WM lesioning. Cocaine-in-
duced disruption of the retinoic acid pathway in oligo-
dendrocytes, therefore, may be responsible in part for the
WM loss observed after paradigms of chronic abuse.
In our study, the cocaine-induced deficits in WM pro-
tein levels were normalized by the GLT1 activator ceftri-
axone, suggesting a glutamate-related mechanism may
be involved. Early studies reported that acute cocaine ex-
posure increases extracellular glutamate in the NA.7,30 It is
also reported that reintroduction to cocaine after forced
abstinence elicits an increase in extracellular glutamate
in the NA greater than increases observed after initial
cocaine exposure.8,31 Moreover, recent studies by Sond-
heimer and Knackstedt19 report that in a rat model of
cocaine abuse, ceftriaxone prevented the induction of
cocaine sensitization. In light of these findings, all mice
received a single challenge dose of cocaine (15 mg/kg
i.p.) before euthanasia 24 hours later. Numerous studies
from Kalivas et al10 have expanded on these findings to
show that decreased extracellular glutamate levels in the
NA after withdrawal from chronic cocaine potentiates re-
instatement of cocaine-seeking behavior.2,8,32 Studies
from Kalivas et al10 also show that the effects can be
prevented by restoring extracellular glutamate levels.
Thus, one potential explanation for the observations in our
study is that the elevation in extracellular glutamate after
cocaine challenge, coupled with the upregulation of
N-methyl-D-aspartic acid and -amino-3-hydroxy-5-methyl-
4-isoxazole-propanoic acid receptors, which likely occurred
during cocaine withdrawal, may have resulted in glutamate-
mediated toxicity that was manifested as oligodendrocyte
apoptotic death and a reduction in WM proteins. It is also
important to note that the deficits in WM protein levels
became more pronounced during the course of with-
drawal. WM protein levels after 30 days of withdrawal
were only 50% of the control levels in some cases (Figure
1), whereas, a shorter withdrawal interval of 2 days re-
sulted in significant WM loss, but to a lesser degree than
a 30-day withdrawal (data not shown). These observa-
tions are supported by previous studies showing that
temporal decreases in basal glutamate levels are more
pronounced at later stages of withdrawal.6,33 Thus, re-
peated cocaine exposure followed by treatment with
ceftriaxone during the withdrawal interval may increase the
expression of GLT1, an effect that is hypothesized to offset
the upregulation of N-methyl-D-aspartic acid and -amino-
3-hydroxy-5-methyl-4-isoxazole-propanoic acid receptors.
Although neurons are reported to be most affected by
increased extracellular glutamate on acute cocaine ad-
ministration,30 the loss of WM proteins suggests damage
to oligodendrocytes. In support of glutamate-mediated
loss of WM, recent studies in multiple sclerosis, stroke,
and cerebral palsy show that oligodendrocytes are dam-
aged by glutamate excitotoxicity. However, other effects
of ceftriaxone, such as activation of the GLT1 transporter,
independent of changes in expression, reduction of T-
cell activation by modulation of cellular antigen-presen-
tation, or metal ion chelation cannot be excluded18,34 as
contributors to our observations.
Important studies from Hanlon et al5 report that when
compared to cocaine users that had been abstinent for atleast 1 month (n  24), current cocaine users (n  24)
had significantly lower WM tissue densities.5 Moreover,
WM densities for abstinent cocaine users were similar to
those of nondrug user controls, suggesting recovery of
cocaine-induced WM loss upon prolonged abstinence.
Given these findings, it is possible that with a longer
withdrawal period in cocaine-treated mice, WM protein
levels may have returned to normal in the absence of
ceftriaxone. Expanded studies that include dose and
time course responses are required to understand and
characterize both the mechanisms through which co-
caine decreases WM proteins and how ceftriaxone pre-
vents this loss. However, the observation that ceftriaxone
negates cocaine-induced WM loss provides clues as to
the mechanism through which cocaine may exert its ef-
fects on white matter protein levels. One of the limitations
of our study is the fact that a group of cocaine-treated
withdrawal mice without challenge was not included. The
NA plays an integral role in drug reward, as it receives
dopaminergic projections from the ventral tegmental area
and glutamatergic projections from the prefrontal cor-
tex.35 Dysfunction of the NA is associated with impulsive
decision-making, anxiety, and major depressive disor-
der.36,37 Thus, future studies addressing WM loss and
connectivity networks are required to understand co-
caine-mediated WM loss and ceftriaxone-induced inter-
ventions in myelin disruptions more clearly.
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